News | May 21, 2018

Intramural Needle Ablation Effective for Refractory Ventricular Arrhythmias

Intramural Needle Ablation Effective for Refractory Ventricular Arrhythmias. #HRS2018

May 21, 2018 — The available electrophysiology catheter ablation technologies are not designed for use in the ventricular anatomy, so a new needle ablation catheter from Biosense Webster was tested in a study to assessed the safety.[1] The six-month data from the study was presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

All of the patients had failed using a standard approach and then using the needle we were able to get rid of their tachycardia

All 31 patients included in the trial failed standard ablation and medical therapy. However, the needle-based system was able to eliminate their tachycardia. 

Intramural origin is an important cause of ventricular arrhythmia (VA) ablation failure that we are attempting to address with an irrigated needle ablation catheter. This study assessed the safety and six-month outcome of irrigated needle ablation in patients with sustained monomorphic ventricular tachycardia (VT) and structural heart disease or nonsustained ventricular arrhythmia and left ventricular (LV) dysfunction not responsive to antiarrhythmic drugs and standard catheter ablation. 

Patients were enrolled at three centers. At putative target sites selected based on endocardial mapping, the 27 gauge needle was deployed up to 10 mm into the myocardium for recording and pace mapping. Then irrigated with contrast/saline for radiofrequency (RF) ablation with current titrated to a maximum needle temperature of 60 degrees Centigrade.

Irrigated needle ablation was performed in 31 patients at the three centers. Most patients had nonischemic heart disease (NICM) with sustained monomorphic VT (table). A median of 15 RF needle applications per patient were delivered to selected RV/LV septum and free wall sites.

 

Links to all the Heart Rhythm 2018 Late-breaking Studies

 

Reference:

1. Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias. ClinicalTrials.gov Identifier: NCT03204981. https://clinicaltrials.gov/ct2/show/NCT03204981

 

#HRS2018 #HRS18


Related Content

News

May 15, 2024 —CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac ...

Home May 15, 2024
Home
News

May 13, 2024 — Innovative Health, Inc. announced that recent growth in single-use device reprocessing has delivered ...

Home May 13, 2024
Home
News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
Subscribe Now